The ALS Society of Canada (ALS Canada) is committed to Canada’s contribution to global ALS research. We’re excited to share our involvement in the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), led by the Foundation for the National Institutes of Health (FNIH) in the United States. This innovative initiative brings together public and private partners, including the (U.S.) National Institutes of Health, leading research institutions, pharmaceutical and biotechnology companies, and patient advocacy groups. By gathering a comprehensive resource for data sharing and analysis, identifying reliable biomarkers of the disease, and developing patient-informed clinical outcome assessments, AMP ALS aims to drive forward personalized drug development and potentially enable earlier diagnosis of ALS.
“AMP ALS is the kind of collaborative initiative we have needed for a long time. There have been many amazing, independent ALS research initiatives worldwide, but their true power will be revealed when we bring them all together,” says David Taylor, Vice-President of Research and Strategic Partnerships at ALS Canada. “ALS Canada is proud to partner with these great organizations, sharing the common goal of accelerating our understanding and treatment of ALS. Together, through AMP ALS, we will change the world for this disease.”
As a partner, ALS Canada will contribute funding to AMP ALS over the next five years. In this collaboration, we’ll explore and advocate for opportunities to integrate data from CAPTURE ALS (Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS), a Canadian platform that unites people living with ALS, physicians, and researchers working to identify and analyze diverse biological and clinical characteristics of people living with ALS. Data collected from CAPTURE ALS can provide opportunities to accelerate the development of effective treatments for the disease.
Together, these efforts have the potential to accelerate treatment development and improve outcomes for people living with ALS.
ACCELERATING MEDICINES PARTNERSHIP® and AMP® are registered service marks of the U.S. Department of Health and Human Services.